drugset / Trial / NCT01202279

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

NCT01202279

Phase 4 Completed 1179 enrolled Reckitt Benckiser Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo

Timeline

Start
2009-10
Primary completion
2010-04
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Guaifenesin Small molecule 1200 mg
Subject Pseudoephedrine Small molecule 120 mg